Burkitt Lymphoma clinical trials

Explore recruiting burkitt lymphoma clinical trials.

Recruiting burkitt lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Burkitt Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

HOVON 127 BL / SAKK 37/16: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

Belgium, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

LIGHTBEAM-U01-Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants with Hematologic Malignancies or Solid Tumors.

Hungary, Denmark, Netherlands, Czechia, Sweden, Italy +6 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy C – Relapsed/Refractory Burkitt Lymphoma (BL)

Netherlands, France, Austria, Spain, Italy, Germany +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Burkitt Lymphoma trials by city

Burkitt Lymphoma in Toronto Burkitt Lymphoma in Vancouver Burkitt Lymphoma in Montreal Burkitt Lymphoma in Calgary Burkitt Lymphoma in Edmonton Burkitt Lymphoma in Ottawa Burkitt Lymphoma in Winnipeg Burkitt Lymphoma in Quebec City Burkitt Lymphoma in Hamilton Burkitt Lymphoma in Kitchener Burkitt Lymphoma in London Burkitt Lymphoma in Halifax Burkitt Lymphoma in New York Burkitt Lymphoma in Los Angeles Burkitt Lymphoma in Chicago Burkitt Lymphoma in Houston

Burkitt Lymphoma clinical trials

Recruiting burkitt lymphoma studies right now

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia

Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Also recruiting in Europe

HOVON 127 BL / SAKK 37/16: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

LIGHTBEAM-U01-Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants with Hematologic Malignancies or Solid Tumors.

A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy C – Relapsed/Refractory Burkitt Lymphoma (BL)

Burkitt Lymphoma trials by city

Other conditions